PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'Janssen Vaccines & Prevention, Leiden, the Netherlands.\', \'Janssen Research & Development, Titusville, NJ, USA.\', \'Brighton Collaboration, A Program of the Task Force for Global Health, Decatur, GA, USA.\', \'Independent Adviser, United Kingdom.\', \'Department of Molecular Genetics and Microbiology, University of Florida, Gainesville, FL, USA.\', \'Janssen Pharmaceutica NV, Beerse, Belgium.\']
?:citedBy
  • -1
?:creator
?:doi
  • S0264-410X(20)31160-910.1016/j.vaccine.2020.09.018
?:doi
?:hasPublicationType
?:journal
  • Vaccine
is ?:pmid of
?:pmid
?:pmid
  • 33676782
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • 1.863
?:rankingScore_hIndex
  • 159
is ?:relation_isRelatedTo_publication of
?:title
  • Vaccines based on replication incompetent Ad26 viral vectors: Standardized template with key considerations for a risk/benefit assessment.
?:type
?:year
  • 2021

Metadata

Anon_0  
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://purl.org/net/provenance/ns#DataItem>
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://www.w3.org/2004/03/trix/rdfg-1/Graph>
<http://xmlns.com/foaf/0.1/primaryTopic> <https://research.tib.eu/covid-19/entity/33676782>
<http://xmlns.com/foaf/0.1/topic> Anon_0
<http://www.ontologydesignpatterns.org/cp/owl/informationrealization.owl#realizes> <https://research.tib.eu/covid-19/data/entity/33676782>
<http://purl.org/net/provenance/ns#createdBy>
Anon_1   (more)
expand all